Quest Diagnostics Inc. (DGX)
Quest Diagnostics Inc. (DGX) is a leading provider of diagnostic testing, information, and services that help clinicians, health plans, and laboratories improve patient care. Founded in 1967 and headquartered in Irving, Texas, the company offers a broad range of laboratory testing services, including clinical chemistry, molecular diagnostics, and pathology, supporting healthcare providers with insights to inform treatment decisions.
Dividend History
Investors can expect a dividend payout of $0.80 per share, scheduled to be distributed in 30 days on October 20, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 20, 2025 | $0.80 | 2025-10-03 | 2025-10-03 |
| July 21, 2025 | $0.80 | 2025-07-07 | 2025-07-07 |
| April 21, 2025 | $0.80 | 2025-04-07 | 2025-04-07 |
| January 29, 2025 | $0.75 | 2025-01-14 | 2025-01-14 |
| October 21, 2024 | $0.75 | 2024-10-04 | 2024-10-04 |
Dividends Summary
- Quest Diagnostics Inc. has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 61 days ago, on July 21, 2025
- The highest dividend payed out to investors during this period was $0.8 per share
- The average dividend paid during this period was $0.36 per share.
Company News
Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on October 20, 2025, to shareholders of record as of October 3, 2025.
The North American Autoimmune Disease Diagnostics Market is projected to grow from $1.96 billion in 2024 to $3.5 billion by 2033, driven by rising autoimmune disease prevalence, technological advancements, and increased healthcare investments.
Quest Diagnostics, a leading healthcare testing specialist, reported strong Q4 2024 results, beating analyst estimates on both revenue and earnings. The company's revenue grew 15% year-over-year, and it provided positive guidance for 2025, indicating continued growth in the aging American population's healthcare needs.
Labcorp reported strong Q2 2024 results, with adjusted EPS up 15.2% and revenues up 6.2% year-over-year. The company saw organic growth in its Diagnostics Laboratories segment, but cut its full-year adjusted EPS guidance due to the dilution impact of the Invitae acquisition.
Baird raised the price target for Quest Diagnostics shares to $153 from $145, citing the company's strategic partnerships, including a new deal with LifeLabs, as well as the integration of the Allina model into their valuation.
